Clinical Trial

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Recruiting
View on ClinicalTrials.gov →
Summary
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-03
Trial Details
NCT Number NCT07243782
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
Enrollment 76 participants
Start Date 2025-12-22
Primary Completion 2027-06-15 (estimated)
Study Completion 2027-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-05